日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE(2)-receptor E-type 4 (EP4), in patients with advanced cancers

首次人体 I 期研究,评估免疫调节剂 E7046(一种 PGE(2) 受体 E 型 4 (EP4) 拮抗剂)在晚期癌症患者中的疗效

Hong, David S; Parikh, Aparna; Shapiro, Geoffrey I; Varga, Andrea; Naing, Aung; Meric-Bernstam, Funda; Ataman, Özlem; Reyderman, Larisa; Binder, Terri A; Ren, Min; Liu, Mingjie; Dayal, Satish; Siu, Amy Y; Sachdev, Pallavi; Xu, Lucy; Bhagawati-Prasad, Vijay; Tchakov, Ilian; Ooi, Chean Eng; Bao, Xingfeng; Marabelle, Aurelien

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

从肿瘤内部发起进攻:专家建议开发人肿瘤内免疫疗法(HIT-IT)

Marabelle, A; Andtbacka, R; Harrington, K; Melero, I; Leidner, R; de Baere, T; Robert, C; Ascierto, P A; Baurain, J-F; Imperiale, M; Rahimian, S; Tersago, D; Klumper, E; Hendriks, M; Kumar, R; Stern, M; Öhrling, K; Massacesi, C; Tchakov, I; Tse, A; Douillard, J-Y; Tabernero, J; Haanen, J; Brody, J